B
테라젠이텍스
066700KOSDAQ의약품 제조업56.5 / 100
Reference Date: 2026-07-24
Financial Score28.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE significantly exceeds the industry average but Operating Profit is on a declining trend. Slightly down 2.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Teragen I-teks operates primarily in pharmaceutical manufacturing and sales, as well as genomic sequencing services. Its subsidiaries, Lead Pharm and Teragen Healthcare, specialize in specialty drug distribution and non-drug medical product sales, respectively. Additionally, Teragen Bio and overseas subsidiaries are expanding genomic analysis services into the Chinese market.
Number of Employees
222people
Average Salary
50.5M KRW
Score Calculation Basis
Detailed Financial Score
PER
6.71Industry Average 11.236.5Point
Lower than industry avg (good)
PBR
0.46Industry Average 0.815.5Point
Lower than industry avg (good)
ROE
8.11Industry Average 4.017.0Point
2.0x industry avg (excellent)
Debt Ratio
5.84Industry Average 12.436.5Point
Half of industry avg (excellent)
Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲10.7% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼5.1% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -0.4% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (6%, downtrend)
Current 1,987Won52-week high 3,31552-week low 1,888
1-month return2.0Point
1m -2.60% (slight drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral전환가액의조정2026-07-20
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-20